Kenneth Gruber

Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020.